

UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY

NICHOLAS MILLER, Individually and On Behalf of All
Others Similarly Situated,

Plaintiff,

v.

EAGLE PHARMACEUTICALS, INC., SCOTT TARRIFF, and
BRIAN CAHILL,

Defendants.

Case No. 2:23-CV-23011-MAH

**SUMMARY NOTICE OF (I) PENDENCY OF CLASS ACTION, CERTIFICATION OF
SETTLEMENT CLASS, PROPOSED SETTLEMENT AND PLAN OF ALLOCATION;
(II) SETTLEMENT FAIRNESS HEARING; AND (III) MOTION FOR AN AWARD OF
ATTORNEYS' FEES AND REIMBURSEMENT OF LITIGATION EXPENSES**

**TO: All persons and entities who purchased the publicly traded common stock of Eagle Pharmaceuticals, Inc. between
August 9, 2022 and October 1, 2024, both dates inclusive (the "Settlement Class")¹:**

**PLEASE READ THIS NOTICE CAREFULLY, YOUR RIGHTS WILL BE AFFECTED BY A CLASS ACTION LAWSUIT
PENDING IN THIS COURT.**

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of
the Federal Rules of Civil Procedure and an Order of the United
States District Court for the District of New Jersey, that the
above-captioned litigation (the "Action") has been certified as a
class action on behalf of the Settlement Class, except for certain
persons and entities who are excluded from the Settlement Class
by definition as set forth in the full Notice of (I) Pendency of
Class Action, Certification of Settlement Class, and Proposed
Settlement; (II) Settlement Fairness Hearing; and (III) Motion for
an Award of Attorneys' Fees and Reimbursement of Litigation
Expenses (the "Notice").

YOU ARE ALSO NOTIFIED that Plaintiffs in the Action
have reached a proposed settlement of the Action for \$9,500,000
in cash (the "Settlement"), that, if approved, will resolve all
claims in the Action.

A hearing will be held on August 19, 2026, at 2:00 p.m.,
before the Honorable Michael A. Hammer at the Martin Luther
King Building & U.S. Courthouse, 50 Walnut Street, Newark, NJ
07101, to determine (i) whether the proposed Settlement should
be approved as fair, reasonable, and adequate; (ii) whether the
Action should be dismissed with prejudice against Defendants,
and the Releases specified and described in the Stipulation and
in the Notice should be granted; (iii) whether the proposed Plan
of Allocation should be approved as fair and reasonable; and (iv)
whether Lead Counsel's application for an award of attorneys'
fees and reimbursement of expenses should be approved.

**If you are a member of the Settlement Class, your rights
will be affected by the pending Action and the Settlement,
and you may be entitled to share in the Settlement Fund.** The
Notice and Proof of Claim and Release Form ("Claim Form"),
can be downloaded from the website maintained by the Claims
Administrator, www.EaglePharmaSecuritiesSettlement.com. You
may also obtain copies of the Notice and Claim Form by
contacting the Claims Administrator at *Eagle Pharmaceuticals
Securities Litigation*, c/o Epig, P.O. Box 4790, Portland, OR
97208-4790, 1-877-313-8718.

If you are a member of the Settlement Class, in order to be
eligible to receive a payment under the proposed Settlement, you
must submit a Claim Form postmarked, or received by, no later
than **October 16, 2026**. If you are a Settlement Class Member
and do not submit a proper Claim Form, you will not be eligible
to share in the distribution of the net proceeds of the Settlement
but you will nevertheless be bound by any judgments or orders
entered by the Court in the Action.

If you are a member of the Settlement Class and wish to
exclude yourself from the Settlement Class, you must submit a
request for exclusion such that it is received by, or postmarked,
no later than **July 29, 2026**, in accordance with the instructions
set forth in the Notice. If you properly exclude yourself from
the Settlement Class, you will not be bound by any judgments
or orders entered by the Court in the Action and you will not be
eligible to share in the proceeds of the Settlement.

Any objections to the proposed Settlement, the proposed
Plan of Allocation, or Lead Counsel's motion for attorneys' fees
and reimbursement of expenses, must be filed with the Court and
delivered to Lead Counsel and Defendants' Counsel such that
they are received by, or postmarked, no later than, **July 29, 2026**,
in accordance with the instructions set forth in the Notice.

**Please do not contact the Court, the Clerk's office, Defendants,
or their counsel regarding this notice. All questions about
this notice, the proposed Settlement, or your eligibility to
participate in the Settlement should be directed to Lead
Counsel or the Claims Administrator.**

Requests for the Notice and Claim Form should be made to:

Eagle Pharmaceuticals Securities Litigation
c/o Epig

P.O. Box 4790

Portland, OR 97208-4790

Toll-free Telephone: 877-313-8718

Email: Info@EaglePharmaSecuritiesSettlement.com

Inquiries, other than requests for the Notice and Claim
Form, should be made to Lead Counsel:

GLANCY PRONGAY WOLKE & ROTTER LLP

Garth Spencer, Esq.

1925 Century Park East, Suite 2100

Los Angeles, CA 90067

Telephone: (310) 201-9150

Email: settlements@glancylaw.com

By Order of the Court

¹ All capitalized terms used in this Summary Notice that are
not otherwise defined herein have the meanings ascribed to
them in the Stipulation and Agreement of Settlement dated
March 13, 2026 (the "Stipulation"), which is available at
www.EaglePharmaSecuritiesSettlement.com.